Today’s Short Interest: Is Buying Cepheid Incorporated (NASDAQ:CPHD) Here Good Idea?

November 30, 2016 - By Clifton Ray   ·   0 Comments

Today's Short Interest: Is Buying Cepheid Incorporated (NASDAQ:CPHD) Here Good Idea?

The stock of Cepheid Incorporated (NASDAQ:CPHD) registered an increase of 4.44% in short interest. CPHD’s total short interest was 2.52 million shares in November as published by FINRA. Its up 4.44% from 2.41M shares, reported previously. With 1.51M shares average volume, it will take short sellers 2 days to cover their CPHD’s short positions. The short interest to Cepheid Incorporated’s float is 3.82%. The stock closed at $52.95 during the last session. It is down 48.61% since April 6, 2016 and is uptrending. It has outperformed by 43.38% the S&P500.

Cepheid is a molecular diagnostics company. The company has a market cap of $3.87 billion. The Firm develops, makes and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. It currently has negative earnings. The Company’s systems enable molecular testing for organisms and genetic diseases by automating otherwise complex manual laboratory procedures.

Insitutional Activity: The institutional sentiment decreased to 0.98 in 2016 Q2. Its down 0.34, from 1.32 in 2016Q1. The ratio dived, as 25 funds sold all Cepheid shares owned while 57 reduced positions. 32 funds bought stakes while 76 increased positions. They now own 68.03 million shares or 1.80% less from 69.27 million shares in 2016Q1.
Vanguard Incorporated last reported 0.01% of its portfolio in the stock. Blackrock Gru Ltd owns 83,628 shares or 0% of their US portfolio. Capital Mgmt has invested 1.42% of its portfolio in Cepheid (NASDAQ:CPHD). Proshare Advsrs Limited Co holds 0% or 11,310 shares in its portfolio. Fmr Limited Company accumulated 0.01% or 1.91 million shares. Tfs Capital Limited Liability has 49,901 shares for 0.28% of their US portfolio. The New York-based Gabelli Funds Ltd Limited Liability Company has invested 0.04% in Cepheid (NASDAQ:CPHD). Victory Capital Inc accumulated 0% or 753 shares. Riverbridge Ptnrs Ltd Liability Co holds 2.35% of its portfolio in Cepheid (NASDAQ:CPHD) for 3.68 million shares. Nordea Invest Mgmt Ab accumulated 0% or 22,010 shares. Mizuho Asset Mngmt Coltd accumulated 2,230 shares or 0.01% of the stock. Daiwa Secs Group Inc last reported 192 shares in the company. Morgan Stanley holds 353,232 shares or 0% of its portfolio. Champlain Inv Prns last reported 3.44 million shares in the company. Eagle Asset holds 0.06% or 279,240 shares in its portfolio.

Insider Transactions: Since August 2, 2016, the stock had 0 insider purchases, and 3 sales for $43,660 net activity. 287 Cepheid (NASDAQ:CPHD) shares with value of $10,378 were sold by Campbell Scott A..

Cepheid (NASDAQ:CPHD) Ratings Coverage

Out of 18 analysts covering Cepheid (NASDAQ:CPHD), 3 rate it a “Buy”, 1 “Sell”, while 14 “Hold”. This means 17% are positive. Cepheid has been the topic of 43 analyst reports since July 24, 2015 according to StockzIntelligence Inc. The firm has “Equal-Weight” rating given on Wednesday, June 15 by Morgan Stanley. On Friday, July 24 the stock rating was downgraded by Evercore to “Sell”. The firm has “Hold” rating by Needham given on Tuesday, September 6. Mizuho maintained the stock with “Buy” rating in Wednesday, October 21 report. The firm earned “Neutral” rating on Wednesday, September 7 by BTIG Research. The firm has “Hold” rating by Canaccord Genuity given on Wednesday, October 21. The firm has “Buy” rating given on Friday, August 14 by Mizuho. The stock of Cepheid (NASDAQ:CPHD) has “Buy” rating given on Wednesday, October 14 by Needham. Jefferies maintained the shares of CPHD in a report on Wednesday, August 17 with “Hold” rating. The rating was maintained by Robert W. Baird on Wednesday, September 7 with “Outperform”.

CPHD Company Profile

Cepheid, incorporated on March 4, 1996, is a molecular diagnostics company. The Firm develops, makes and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic diseases by automating otherwise complex manual laboratory procedures. Molecular testing involves various time-intensive steps, including sample preparation, Deoxyribonucleic acid (DNA) amplification and detection. The Company’s systems integrate these steps and analyze biological samples in test cartridges. The Company’s primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The Firm also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

More notable recent Cepheid (NASDAQ:CPHD) news were published by: Bloomberg.com which released: “Danaher Buys Cepheid for $4 Billion in First Deal Since Spinoff” on September 06, 2016, also Prnewswire.com with their article: “Danaher Completes Acquisition Of Cepheid” published on November 04, 2016, Prnewswire.com published: “Cepheid Announces Receipt of Required Regulatory Clearances in Proposed …” on October 24, 2016. More interesting news about Cepheid (NASDAQ:CPHD) were released by: Prnewswire.com and their article: “Cepheid Announces Expansion Of The Most Comprehensive Molecular C. Difficile …” published on September 15, 2016 as well as Streetinsider.com‘s news article titled: “Danaher (DHR) Announces Completion of Cepheid (CPHD) Acquisition” with publication date: November 07, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>